Publication | Closed Access

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

Metastatic Breast CancerBreast OncologyMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyLba15 Primary OutcomeCancer TreatmentOncology